J. Taboulet et al., Calcitonin receptor polymorphism is associated with a decreased fracture risk in post-menopausal women, HUM MOL GEN, 7(13), 1998, pp. 2129-2133
High bone resorption by the osteoclast results in osteoporosis, a disease a
ffecting 40% of women after the menopause. Calcitonin, used to treat osteop
orosis, inhibits bone resorption via receptors located on the osteoclasts,
Two alleles of the calcitonin receptor gene (CTR) exist: a base mutation T-
->C in the third intracellular C-terminal domain changes a proline (CCG) at
position 447 to a leucine (CTG). We therefore studied the distribution of
these alleles in a cohort of 215 post-menopausal Caucasian women suffering
or not from osteoporotic fractures. The region of interest within the point
mutation was amplified by PCR and screened for single strand conformation
polymorphism. This work was followed by DNA sequencing of the fragments amp
lified. We found that bone mineral density (BMD) at the femoral neck was si
gnificantly higher in heterozygous subjects with the Rr genotype compared w
ith the homozygous leucine (RR) and homozygous proline (rr) genotypes, Also
, a decreased fracture risk was observed in heterozygote subjects. In concl
usion, our results suggest that polymorphism of CTR could be associated wit
h osteoporotic fractures and BMD in a population of post-menopausal women.
CTR heterozygotes could produce both alleles of the receptor,The heterozygo
us advantage effect of Rr subjects could explain their protection against o
steoporosis: higher bone density and decreased fracture risk. Establishing
the genotype of the CTR gene in post-menopausal women could be of value in
evaluating their risk of developing fractures.